Suven Pharma
Ticker >

Suven Pharma share price

Suven Pharmaceuticals Ltd.

NSE: SUVENPHAR BSE: 543064 SECTOR: Pharmaceuticals & Drugs  49k   289   43

659.70
+12.90 (1.99%)
NSE: 26 Apr 04:02 PM

Price Summary

Today's High

₹ 664.5

Today's Low

₹ 648

52 Week High

₹ 768

52 Week Low

₹ 468.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 16793.65 Cr.

Enterprise Value

₹ 16816.58 Cr.

No. of Shares

25.46 Cr.

P/E

44.02

P/B

8.39

Face Value

₹ 1

Div. Yield

0.92 %

Book Value (TTM)

₹  78.6

CASH

₹ 46.23 Cr.

DEBT

₹ 69.16 Cr.

Promoter Holding

50.1 %

EPS (TTM)

₹  14.99

Sales Growth

0.75%

ROE

26.46 %

ROCE

34.48%

Profit Growth

-22.49 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year0.75%
3 Year16.84%
5 YearNA

Profit Growth

1 Year-22.49%
3 Year17%
5 YearNA

ROE%

1 Year26.46%
3 Year34.34%
5 Year32.33%

ROCE %

1 Year34.48%
3 Year41.81%
5 Year39.1%

Debt/Equity

0.0395

Price to Cash Flow

34.69

Interest Cover Ratio

46.4500976631445

CFO/PAT (5 Yr. Avg.)

0.888811884986431

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 50.1 0
Dec 2023 60 0
Sep 2023 60 0
Jun 2023 60 0
Mar 2023 60 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 17.0034747236509% for the Past 3 years.
  • The company has shown a good revenue growth of 16.843985966062% for the Past 3 years.
  • Company has been maintaining healthy ROE of 34.3421797678525% over the past 3 years.
  • Company has been maintaining healthy ROCE of 41.8066658799437% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 46.4500976631445.
  • The Company has been maintaining an effective average operating margins of 44.771851560384% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 51.2866993839954 days.
  • Company has a healthy liquidity position with current ratio of 3.6832386592053.
  • The company has a high promoter holding of 50.1%.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 348.49 364.39 344.03 224.62 212.83
Total Expenditure 201.42 189.76 174.14 127.27 144.69
Operating Profit 147.07 174.63 169.88 97.35 68.14
Other Income 12.51 10.76 10.06 14.2 13.97
Interest 1.38 2.29 1.15 0.5 1.27
Depreciation 10.91 10.63 11.15 10.48 11.33
Exceptional Items 0 0 0 0 0
Profit Before Tax 147.29 172.46 167.65 100.57 69.5
Tax 37.82 42.3 43.35 25.85 17.14
Profit After Tax 109.47 130.16 124.29 74.73 52.36
Adjusted EPS (Rs) 4.3 5.11 4.88 2.94 2.06

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 377.83 833.79 1009.72 1320.22 1330.08
Total Expenditure 206.28 449 566.68 737.94 739.65
Operating Profit 171.55 384.79 443.04 582.28 590.43
Other Income 0.6 18.12 14.24 187.79 44.55
Interest 2.79 21.81 11.66 8.53 12.75
Depreciation 11.5 23.51 31.64 39.1 42.84
Exceptional Items 0 0 0 0 0
Profit Before Tax 157.87 357.59 413.98 722.45 579.39
Tax 48.59 87.51 105.33 164.35 146.79
Net Profit 109.27 270.08 308.65 558.1 432.6
Adjusted EPS (Rs.) 0 10.61 12.12 21.92 16.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 0 12.73 25.46 25.46 25.46
Total Reserves 590.29 770.1 1039.73 1495.24 1723.92
Borrowings 0 91.25 35.59 28.44 4.56
Other N/C liabilities 35.12 36.42 38.32 46.75 50.21
Current liabilities 190.67 319.85 321.49 346.23 298.5
Total Liabilities 816.08 1230.35 1460.59 1942.11 2102.65
Assets
Net Block 270.9 356.74 441.16 534.19 512.03
Capital WIP 111.07 101.56 96.15 29.99 164.81
Intangible WIP 0 0.14 0.17 0 0
Investments 0.07 245.65 245.65 118.67 317.21
Loans & Advances 11.02 15.06 10.85 13.07 9.16
Other N/C Assets 0.22 0.2 0.16 0 0
Current Assets 422.8 511 666.45 1246.19 1099.44
Total Assets 816.08 1230.35 1460.59 1942.11 2102.65
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 157.87 357.59 413.98 722.45 579.39
Adjustment 13.93 33.35 36.48 -110.18 28.33
Changes in Assets & Liabilities -88.33 54.22 -12.19 -190.63 22.24
Tax Paid -33.06 -86.41 -109.44 -151.74 -145.79
Operating Cash Flow 50.4 358.75 328.84 269.89 484.17
Investing Cash Flow -65.48 -366.65 -257.66 -90.29 -235.57
Financing Cash Flow 25.98 8.57 -75.66 -156.48 -235.79
Net Cash Flow 10.9 0.67 -4.49 23.12 12.81

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 60.00 60.00 60.00 60.00 50.10
berhyanda limited - - 50.10 50.10 50.10
jasti property and equity... 60.00 60.00 9.90 9.90 -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 40.00 40.00 40.00 40.00 49.90
dsp equity savings fund - - 3.26 - 5.91
goldman sachs funds - gol... - - - - 1.11
hsbc midcap fund 1.79 1.79 - 1.55 1.57
investor education and pr... 0.14 0.14 - - 0.14
jasti property and equity... - - - - 9.90
uti-unit linked insurance... 3.88 - - - 3.76
amansa holdings private l... 2.56 2.56 2.38 2.38 -
dsp healthcare fund - - - 3.83 -
investor education and pr... - - 0.14 0.14 -
uti small cap fund - 3.92 3.86 3.95 -
hsbc multi cap fund - - 1.48 - -
tata flexi cap fund - - 1.15 - -
alpha alternatives msar l... - 1.09 - - -
rambabu chirumamilla 2.23 2.23 - - -
tata aia life insurance c... 2.15 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

USFDA completes inspections at Suven Pharmaceuticals’ API, Formulations facilities23 Feb 2024, 5:15PM Suven Pharma - Quaterly Results5 Feb 2024, 5:19PM Suven Pharma - Quaterly Results5 Feb 2024, 5:19PM Suven Pharma - Quaterly Results5 Feb 2024, 5:19PM Suven Pharmaceuticals informs about disclosure6 Dec 2023, 2:46PM Suven Pharmaceuticals informs about investor presentation24 Nov 2023, 5:24PM Suven Pharma - Quaterly Results9 Nov 2023, 5:49PM Suven Pharma - Quaterly Results9 Nov 2023, 5:49PM Suven Pharmaceuticals informs about letter of offer11 Oct 2023, 2:50PM Advent International completes acquisition of Suven Pharmaceuticals30 Sep 2023, 3:56PM Suven Pharmaceuticals informs about transcript of conference call14 Aug 2023, 4:34PM Suven Pharma - Quaterly Results8 Aug 2023, 4:14PM Suven Pharma - Quaterly Results8 Aug 2023, 4:14PM Suven Pharma - Quaterly Results8 Aug 2023, 4:14PM Suven Pharmaceuticals informs about disclosure12 Jun 2023, 4:52PM Suven Pharmaceuticals informs about earnings call transcript2 Jun 2023, 4:59PM Suven Pharma - Quaterly Results25 May 2023, 1:41PM Suven Pharma - Quaterly Results25 May 2023, 1:41PM Suven Pharma - Quaterly Results25 May 2023, 1:41PM CCI approves acquisition of up to 76.10% of voting share capital of Suven by Berhyanda 21 Apr 2023, 10:00AM Suven Pharmaceuticals informs about loss of share certificate18 Mar 2023, 12:21PM Suven Pharma - Quaterly Results6 Feb 2023, 1:12PM Suven Pharma - Quaterly Results6 Feb 2023, 1:12PM Suven Pharma - Quaterly Results6 Feb 2023, 1:12PM Suven Pharmaceuticals informs about conference call for investors31 Jan 2023, 11:40AM Suven Pharmaceuticals informs about board meeting30 Jan 2023, 5:16PM Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family26 Dec 2022, 9:42AM Suven Pharmaceuticals informs about open offer 26 Dec 2022, 9:26AM Suven Pharmaceuticals informs about press release 26 Dec 2022, 9:17AM Suven Pharma - Quaterly Results8 Nov 2022, 12:42PM Suven Pharma - Quaterly Results8 Nov 2022, 12:42PM Suven Pharma - Quaterly Results8 Nov 2022, 12:42PM Suven Pharmaceuticals informs about disclosure 3 Nov 2022, 4:20PM Suven Pharmaceuticals’ arm gets EIR from USFDA for pre-approval inspection4 Oct 2022, 2:45PM Suven Pharma - Quaterly Results8 Aug 2022, 1:09PM Suven Pharma - Quaterly Results8 Aug 2022, 1:09PM Suven Pharma - Quaterly Results8 Aug 2022, 1:09PM USFDA completes pre-approval inspection at facility of Suven Pharmaceuticals’ arm 1 Aug 2022, 4:29PM Suven Pharmaceuticals informs about AGM26 Jul 2022, 3:31PM Suven Pharma - Quaterly Results9 May 2022, 1:09PM Suven Pharma - Quaterly Results9 May 2022, 1:09PM Suven Pharma - Quaterly Results9 May 2022, 1:09PM Suven Pharma - Quaterly Results8 Feb 2022, 1:14PM Suven Pharma - Quaterly Results8 Feb 2022, 1:14PM Suven Pharma - Quaterly Results8 Feb 2022, 1:14PM Suven Pharmaceuticals informs about conference call for investors3 Feb 2022, 12:50PM Suven Pharmaceuticals informs about record date2 Feb 2022, 12:39PM Suven Pharmaceuticals’ arm divests stake in Rising Pharma Holdings, Inc14 Dec 2021, 3:58PM Suven Pharma - Quaterly Results6 Nov 2021, 12:52PM Suven Pharma - Quaterly Results6 Nov 2021, 12:52PM

Suven Pharma Stock Price Analysis and Quick Research Report. Is Suven Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Suven Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Suven Pharma cash from the operating activity was Rs 484.1702 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Suven Pharma has a Debt to Equity ratio of 0.0395 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Suven Pharma , the EPS growth was -22.4862705030196 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Suven Pharma has OPM of 44.3908628640176 % which is a good sign for profitability.
     
  • ROE: Suven Pharma have a healthy ROE of 26.4582713699 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Suven Pharma is Rs 659.7. One can use valuation calculators of ticker to know if Suven Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Suven Pharma

Suven Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to our stock analysis page for Suven Pharmaceuticals Ltd., a leading player in the Indian Pharmaceutical Industry. As an Indian long-term stock investor, you are likely always on the lookout for valuable investment opportunities with the potential for growth over time. Ticker provides a comprehensive guide to Suven Pharmaceuticals Ltd.'s stock analysis, offering insights into its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

In addition to providing an in-depth analysis of these key strategies, we offer pre-built screening tools that help investors track the performance of the stock. Ticker also provides downloadable annual reports and quarterly results, allowing you to stay up-to-date with the company’s performance.

Through assessing the balance sheet, quarterly results, and profit and loss, Ticker’s premium features allow for fair value calculation using tools - DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. With these tools, you gain a deeper understanding of the company's financial position, enabling you to make better investment decisions.

Suven Pharmaceuticals Ltd Share Price 

The share price of Suven Pharmaceuticals Ltd. is an important metric for assessing the company's market sentiment and investor perception. Ticker provides the latest share price information and pre-built screening tools to help investors track the stock's performance. By keeping a close eye on market trends, investors can make more informed buying, selling, or holding decisions for Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd Balance Sheet 

Suven Pharmaceuticals Ltd.'s balance sheet offers a window into the company's financial position by providing valuable information on its assets, liabilities, and shareholders’ equity. Through Ticker's premium tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, investors can make fair value calculations for the company. By analyzing the balance sheet, investors can gain a better understanding of the company's relative financial health and stability, providing vital information to guide their investment strategy.

Suven Pharmaceuticals Ltd Annual Report 

The Suven Pharmaceuticals Ltd. annual report gives an in-depth analysis of the company's performance, strategy, and future plans, making it essential reading for investors. Ticker provides annual reports as downloadable files for investors to read and analyze. By studying the annual report, investors can understand the company's business prospects, assess its ability to pay dividends, and make well-informed investment decisions.

Suven Pharmaceuticals Ltd Dividend 

For investors seeking income from their investments, tracking a company's dividend history and making informed decisions accordingly is an essential step. Ticker provides information on Suven Pharmaceuticals Ltd.'s dividend payments and history. By studying dividend payouts, investors can understand the company's fiscal health and predict its ability to pay out future dividends.

Suven Pharmaceuticals Ltd Quarterly Result 

Assessing the quarterly results of Suven Pharmaceuticals Ltd. in terms of revenue, expenses, and profits is essential for long-term investors to gauge the financial performance of the company. As such, Ticker offers downloadable quarterly reports that provide an in-depth analysis of the company's financial position. By understanding the trends and developments highlighted in these reports, investors can make more informed decisions about buying, holding or selling the stock.

Suven Pharmaceuticals Ltd Stock Price 

Tracking the stock price of Suven Pharmaceuticals Ltd. is one of the crucial steps investors must take to assess how the market perceives the company's potential for growth and future prospects. Ticker provides real-time stock price information. Tracking historical stock trends through the website's pre-built screening tools is an excellent way to gain a deeper understanding of market sentiment and assist in making better-informed investment decisions.

Suven Pharmaceuticals Ltd Price Chart 

For technical analysis purposes, visual representation of the company's stock price movements is crucial. As such, Ticker offers price charts of Suven Pharmaceuticals Ltd. By studying historical trends and patterns, investors can develop trading strategies. Moreover, using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis can reinforce their investment approach.

Suven Pharmaceuticals Ltd News 

Being well-informed on the latest news and developments about Suven Pharmaceuticals Ltd. is important for investors looking to make strategic investment decisions. Ticker provides a dedicated news section, covering the latest updates and announcements related to the company. By staying up-to-date with the latest company news, investors can change their investment strategy based on new information and market trends.

Suven Pharmaceuticals Ltd ConcCall Transcripts 

Concall transcripts of Suven Pharmaceuticals Ltd. offer valuable insights into the company's management discussions, strategy, and performance. Ticker offers downloadable concall transcripts. By analyzing the transcripts, investors can keep abreast of key developments and changes, giving them the edge to make informed investment decisions.

Suven Pharmaceuticals Ltd Investor Presentations 

Studying the investor presentations of Suven Pharmaceuticals Ltd. is a smart way to understand the company’s strategy, business model, and long-term growth plans. Ticker offers downloadable investor presentations in a comprehensive format for investors, allowing them to gain a better perspective on the company's performance plans. With our fair value calculation tools, including DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, investors can gauge the long-term growth potential of Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd Promoters 

Promoters are key figures in Suven Pharmaceuticals Ltd.’s success, and understanding them is as critical as balancing the balance sheet. By studying the promoters' shareholding pattern and background, investors can form a better understanding of the management team's motivations, competence, and credibility. Ticker provides comprehensive information on Suven Pharmaceuticals Ltd.'s promoters to assist investors in their research.

Suven Pharmaceuticals Ltd Shareholders 

Knowing and analyzing the shareholding pattern of Suven Pharmaceuticals Ltd. is helpful in determining investor sentiment. Ticker provides information on the company's major shareholders and institutional investors. Understanding investors' interest levels can better assist and inform an individual's investment strategy.

Read More
X